PYC Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6 Verdun St Harry Perkins Institute, Ned...Phone Number
+61861510992Website
www.pyctx.comRevenue
$26.2 MillionStock Symbol
PYCIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About PYC Therapeutics
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.Explore more
PYC Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PYC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if PYC Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at PYC Therapeutics
Earning: See what the market has to say on PYC Therapeutics recently announced quarterly report
Check if PYC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once PYC Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when PYC Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if PYC Therapeutics had a recent Job posting/layoffs
PYC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined PYC Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to PYC Therapeutics
Compare insights from companies similar to PYC Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PYC Therapeutics
$26.2M
51-200
Public
$121.6M
2005
CR
Carol RichardsonCEO & Eo To The Accounts & HR Administrator
Company Profile Activity
Activity Insights
PYC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PYC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PYC Therapeutics.
PYC Therapeutics financials insights
Gather financial insights about PYC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$74.6M
2026
Stock/Share Issuance
$47M
PYC Therapeutics Tech Stack
A closer look at the technologies used by PYC Therapeutics
Most Recent Scoops
Project
PYC Therapeutics has received shareholder approval, with 94.47% of votes in favor, to increase the maximum aggregate annual non-executive director remuneration cap from AUD 300,000 to AUD 1,000,000 per annum, pursuant to Clause 26.2 of the company's constitution and ASX Listing Rule 10.17.
Share Placement, Finance, Governance
Project
PYC Therapeutics has held a pre-IND meeting with the FDA for its Phelan-McDermid syndrome program, with the FDA expressing a preference for a direct multiple ascending dose study, and the company is evaluating this pathway with plans to advance the program into clinical development.
Medical Research, Pharmaceuticals, Clinical Operations
Project
PYC Therapeutics is approaching key near-term milestones in its Polycystic Kidney Disease program, with results from the single ascending dose study set to be released at the American Society of Nephrology meeting in October, alongside a safety review committee for the Phase I-A study and evaluation of safety data from the first patients in the multiple dose study.
Medical Research, Pharmaceuticals, Clinical Operations
Project
PYC Therapeutics is continuing execution in ongoing open-label studies across its two ophthalmology programs to define clinical proof of concept and support transition to registrational trials, with efficacy data updates across both programs expected in the current first half of the year.
Proof of Concept (POC), Clinical Operations
Project
Pharmaceuticals, Clinical Operations
PYC Therapeutics News & Media
PYC Therapeutics Limited (PYCXF) Shareholder/Analyst Call Transcript
PYC Therapeutics Limited (PYCXF) Shareholder/Analyst Call May 21, 2026 8:01 PM EDTCompany ParticipantsRohan Hockings - CEO & Executive...PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
PYC Therapeutics (ASX:PYC) has completed the retail component of a major capital raising, adding approximately $47 million to its funding as the biotechnology company continues to advance its precision medicine programs for genetic diseases.When Will PYC Therapeutics Limited (ASX:PYC) Become Profitable?
We feel now is a pretty good time to analyse PYC Therapeutics Limited's ( ASX:PYC ) business as it appears the company...PYC Therapeutics Secures $146 Million in Entitlement Offer to Advance RNA Therapies
An announcement from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited has successfully completed its Entitlement Offer, raising app...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding PYC Therapeutics
Sign Up For FreeTo access detailed company insights
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding... Read More
